RedHill Biopharma Reports 2016 Second Quarter Financial Results
(Thomson Reuters ONE) -
* RedHill maintains a strong and debt-free balance sheet with $47.7 million in
cash at the end of the second quarter, allowing the Company to continue to
diligently execute its three ongoing Phase III gastrointestinal disease
programs in the U.S. as well as additional clinical programs
* Recent key milestones include:
* First patients dosed in the Phase II study with BEKINDA((TM)) for
diarrhea-predominant irritable bowel syndrome (IBS-D)
* Positive Type B meeting with the FDA supporting the planned confirmatory
Phase III study with RHB-105 for H. pylori infection
* Notice of Allowance from the United States Patent and Trademark Office
(USPTO) for a new patent covering RHB-105
* Positive final results from the Phase I study with YELIVA((TM) )for
advanced solid tumors, confirming that the study successfully met both
primary and secondary endpoints
* Exclusive license agreement with Grupo JUSTE for the commercialization
in Spain of RIZAPORT((TM)) oral thin-film migraine drug
* Research collaboration with National Institutes of Health (NIH) for
potential Ebola treatment
* Upcoming potential milestones include:
* Interim data and safety monitoring board (DSMB) analysis of the ongoing
RHB-104 Phase III study for Crohn's disease
* Final results from the ongoing Phase IIa study with RHB-104 for multiple
sclerosis
* Initiation of three Phase I/II studies with YELIVA((TM)) for additional
oncology and inflammatory indications
* Top-line results from the ongoing Phase III study with BEKINDA((TM)) for
gastroenteritis
* Initiation of a confirmatory Phase III study with RHB-105 for the
treatment of H. pylori infection
TEL-AVIV, Israel, July 26, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd.
(NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), a biopharmaceutical
company primarily focused on development and commercialization of late clinical-
stage, proprietary, orally-administered, small molecule drugs for inflammatory
and gastrointestinal diseases and cancer, today reported its financial results
for the quarter ended June 30, 2016.
The Company will host a conference call on Tuesday, July 26, 2016, at 9:00 am
EDT to review the financial results and business highlights, dial-in details are
included below.
Financial highlights for the quarter ended June 30, 2016(1):
Research and Development Expenses for the second quarter of 2016 were $6.0
million, an increase of $0.9 million, compared to $5.1 million in the second
quarter of 2015. Research and Development Expenses for the six months ended
June 30, 2016 were $10.7 million, an increase of $1.8 million, compared to $8.9
million in the comparable period of 2015. The increase in 2016 resulted
primarily from clinical trial costs related to the ongoing Phase III MAP US
study with RHB-104 (Crohn's disease) and from preparations for several Phase
I/II studies with YELIVA((TM)) for multiple oncology, inflammatory and
gastrointestinal indications.
General, Administrative and Business Development Expenses in the second quarter
of 2016 were $1.2 million, an increase of $0.4 million, compared to $0.8 million
in the second quarter of 2015. General, Administrative and Business Development
Expenses for the six months ended June 30, 2016 were $2.4 million, an increase
of $0.7 million, compared to $1.7 million in the comparable period of 2015. The
increase was mainly due to enhanced business development activities.
Operating Loss in the second quarter of 2016 was $7.2 million, an increase of
$1.3 million, compared to $5.9 million in the second quarter of 2015. Operating
Loss for the six months ended June 30, 2016 were $13.1 million, an increase of
$2.5 million, compared to $10.6 million in the comparable period of 2015. The
increase was mainly due to increases in Research and Development Expenses, as
detailed above.
Net Cash Used in Operating Activities in the second quarter of 2016 was $5.7
million, an increase of $1.0 million, compared to $4.7 million in the second
quarter of 2015. Net Cash Used in Operating Activities for the six months ended
June 30, 2016 was $10.7 million, an increase of $2.6 million, compared to $8.1
million in the comparable period of 2015. The increase mainly reflects the
increase in Operating Loss, as detailed above.
Net Cash Used in Investment Activities in the second quarter of 2016 was $2.9
million, compared to Net Cashed Provided by Investment Activities of $3.5
million in the second quarter of 2015. Net Cash Used in Investment Activities
for the six months ended June 30, 2016 was $7.5 million, an increase of $3.9
million, compared to $3.6 million in the comparable period of 2015. The increase
in Net Cash Used in Investment Activities was mainly due to an increase in bank
deposits and marketable securities in 2016.
Net Cash Provided by Financing Activities in the second quarter of 2016 was $0.1
million, compared to an immaterial amount in the second quarter of 2015. Net
Cash Provided by Financing Activities for the six months ended June 30, 2016 was
$0.1 million, compared to $13.2 million in the comparable period of 2015, which
resulted mainly from the Company's public offering in February 2015.
Cash Balance(2) as of June 30, 2016 was $47.7 million, a decrease of $10.4
million, compared to $58.4 million as of December 31, 2015. The decrease was a
result of the ongoing operations, mainly related to research and development
activities.
"We have achieved several significant clinical and operational milestones this
quarter, while continuing to maintain our financial discipline," said Mr. Micha
Ben Chorin, RedHill's CFO. "With a strong cash position of $47.7 million at the
end of the second quarter we are well-positioned to advance our strategic and
operational plans, including the establishment of commercial operations in the
U.S. During the second quarter, we continued to actively advance our three Phase
III-stage gastrointestinal programs. We are working towards several anticipated
milestones, including interim DSMB analysis of the RHB-104 Phase III study for
Crohn's disease, final results from the Phase IIa study with RHB-104 for
multiple sclerosis, initiation of a confirmatory Phase III study with RHB-105
for the treatment of H. pylori infection and top-line results from the
BEKINDA((TM)) Phase III study for gastroenteritis. In the coming weeks, we
expect to provide a mid-year business update that will highlight the status and
timelines for RedHill's main operations."
Conference Call and Webcast Information:
The Company will host a conference call on Tuesday, July 26, 2016, at 9:00 am
EDT to review the financial results and business highlights.
To participate in the conference call, please dial the following numbers 5-10
minutes prior to the start of the call: United States: +1-877-280-1254;
International: +1-646-254-3388; and Israel: +972-3-763-0147. The access code for
the call is 539724.
The conference call will be broadcasted live and available for replay on the
Company's website, http://ir.redhillbio.com/events.cfm, for 30 days. Please
access the Company's website at least 15 minutes ahead of the conference to
register, download, and install any necessary audio software.
Recent operational highlights:
1. On April 11, 2016, RedHill announced that it had initiated a randomized,
double-blind, placebo-controlled, 2-arm parallel group Phase II clinical
study in the U.S. evaluating the safety and efficacy of BEKINDA((TM)) 12 mg
in patients with diarrhea-predominant irritable bowel syndrome (IBS-D). The
study is expected to be conducted in 12 clinical sites in the U.S. and to
enroll 120 patients who will be randomized 60:40 to receive either
BEKINDA((TM)) 12 mg or a placebo, once daily, for a period of eight weeks.
The primary endpoint for the study is the proportion of patients in each
treatment group with response in stool consistency as compared to baseline,
per U.S. Food and Drug Administration (FDA) guidance definition. Secondary
endpoints include the proportion of patients in each treatment group who are
pain responders and the proportion of patients in each treatment group who
are responders to the combined endpoints of stool consistency and pain, per
FDA guidance definition. RedHill further announced, on June 20, 2016, that
the first patients in the Phase II study had been dosed.
2. On April 18, 2016, RedHill announced that it had concluded a positive Type B
Meeting with the FDA regarding the path to marketing approval of RHB-105 and
the planned confirmatory Phase III study for the treatment of H.
pylori infection. The FDA confirmed, subject to final minutes of the
meeting, the planned two-arm, randomized, double-blind, active comparator
design of the confirmatory Phase III study. Based on FDA feedback, and
subject to successful completion, the planned confirmatory Phase III study,
along with the successfully completed first Phase III study and data from a
supportive PK program, are expected to support a U.S. New Drug Application
(NDA) for RHB-105.
The FDA Type B meeting announcement followed the successful final results
from the first Phase III clinical study with RHB-105 (the ERADICATE Hp
study) reported in March 2016, confirming that the ERADICATE Hp study
successfully met its primary endpoint of superiority over historical
standard-of-care (SoC) eradication rate levels of 70%, with high statistical
significance (p<0.001). The results demonstrated 89.4% efficacy in
eradicating H. pylori infection with RHB-105. RHB-105 has been granted
Qualifying Infectious Disease Product (QIDP) designation by the FDA,
providing a Fast-Track development pathway, as well as Priority Review
status, potentially leading to a shorter review time by the FDA of a NDA, if
filed. If approved, RHB-105 will have a total of 8 years of market
exclusivity.
3. On May 4, 2016, RedHill announced that the U.S. National Cancer Institute
(NCI) has awarded the Medical University of South Carolina (MUSC) a $1.8
million grant to support a broad range of studies on the feasibility of
targeting sphingolipid metabolism for the treatment of a variety of solid
tumor cancers. One component of the studies includes a planned Phase II
study with YELIVA((TM)) (ABC294640) for the treatment of advanced
hepatocellular carcinoma (HCC), the most common primary malignant cancer of
the liver(3). The Phase II study, planned to be initiated in the third
quarter of 2016, will be conducted at MUSC and additional clinical sites and
is intended to evaluate the efficacy and safety of YELIVA((TM)) as a second-
line monotherapy in patients with advanced HCC. The NCI grant covers a five-
year period. The Phase II HCC study will be further supported by additional
funding from RedHill, which acquired the exclusive worldwide rights to
YELIVA((TM)) from Apogee Biotechnology Corp. (Apogee).
4. On June 21, 2016, RedHill announced positive final results from the Phase I
study with YELIVA((TM)) in advanced solid tumors. The results confirmed that
the study successfully met both its primary and secondary endpoints,
demonstrating that YELIVA((TM)) can be safely administered to cancer
patients at doses that provide circulating drug levels that are predicted to
have therapeutic activity, based on levels required in preclinical models.
The study included the first-ever longitudinal analyses of plasma S1P levels
as a potential pharmacodynamic biomarker for activity of a sphingolipid-
targeted drug. Administration of YELIVA((TM)) resulted in a rapid and
pronounced decrease in S1P levels over the first 12 hours, with return to
baseline at 24 hours, which is consistent with clearance of the drug.
YELIVA((TM) )was well tolerated over a prolonged period at doses inducing
the expected pharmacodynamic effects.
5. On June 22, 2016, RedHill announced the publication of an
article(4) demonstrating that the triple combination of the RHB-104 active
components provides excellent synergistic activity in the inhibition of
mycobacterial growth, potentially leading to a new and effective treatment
for Crohn's disease associated with Mycobacterium avium subspecies
paratuberculosis (MAP) infection. The article, entitled "RHB-104 triple
antibiotics combination in culture is bactericidal and should be effective
for treatment of Crohn's disease associated with Mycobacterium
paratuberculosis" describes a pre-clinical study intended to determine the
efficacy of the RHB-104 active components (the antibiotics clarithromycin,
clofazimine and rifabutin) against MAP strains isolated from the blood,
tissue and milk of Crohn's disease patients. The results of the study
demonstrated that the RHB-104 active components, in their individual
concentrations or in dual combinations, were not as effective against all
microorganisms, compared to the triple combination at minimum inhibitory
concentrations level.
6. On July 5, 2016, RedHill and its co-development partner, IntelGenx Corp.
(IntelGenx), announced the signing of an exclusive license agreement with
Grupo JUSTE S.A.Q.F (Grupo JUSTE), for the commercialization of
RIZAPORT((TM)) oral thin-film for acute migraines. Under the terms of the
agreement, RedHill granted Grupo JUSTE the exclusive rights to register and
commercialize RIZAPORT((TM)) in Spain and a right of first refusal for a
predefined term for the territories of Belize, Carribean, Chile, Colombia,
Costa Rica, Dominican Republic, El Salvador, Guatemala, Honduras, Mexico,
Nicaragua, Panama, the Middle East and Morocco. RedHill and IntelGenx are
entitled to receive an upfront payment and additional milestone payments
upon the achievement of certain predefined regulatory and commercial
targets, as well as tiered royalties. Financial terms of the agreement were
not disclosed. The initial term of the agreement is for ten years from the
date of the first commercial sale and shall automatically renew for an
additional two-year term. Commercial launch in Spain is expected to take
place in the second half of 2017.
7. On July 13, 2016, RedHill announced the signing of a research collaboration
agreement with the U.S. National Institute of Allergy and Infectious
Diseases (NIAID), part of the National Institutes of Health (NIH), intended
to evaluate RedHill's proprietary experimental therapy for the treatment of
Ebola virus disease. The new research collaboration follows encouraging
results from preliminary non-clinical studies conducted in conjunction with
the NIAID using RedHill's proprietary experimental therapy. If successful,
this study is intended to provide supportive data for discussions with the
FDA for potential use of the Animal Rule pathway for approval. Ebola virus
disease is a severe and often fatal illness, which can cause severe
hemorrhagic fever in humans and has a mortality rate ranging from 25% to
90%(5). There is currently no FDA approved treatment for Ebola virus
disease.
8. On July 21, 2016, RedHill announced that it had received a Notice of
Allowance from the United States Patent and Trademark Office (USPTO) for a
new patent covering RHB-105. The patent application,
entitled "Pharmaceutical Compositions For The Treatment Of Helicobacter
Pylori"expands RedHill's patent portfolio covering RHB-105 and is expected
to be valid until 2034, once granted. The Company is currently prosecuting
additional U.S. and international patent applications covering RHB-105.
About RedHill Biopharma Ltd.:
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) is a biopharmaceutical company
headquartered in Israel, primarily focused on the development and
commercialization of late clinical-stage, proprietary, orally-administered,
small molecule drugs for the treatment of inflammatory and gastrointestinal
diseases and cancer. RedHill's current pipeline of proprietary products
includes: (i) RHB-105 - an oral combination therapy for the treatment
of Helicobacter pylori infection with successful results from a first Phase III
study; (ii) RHB-104 - an oral combination therapy for the treatment of Crohn's
disease with an ongoing first Phase III study and an ongoing proof-of-concept
Phase IIa study for multiple sclerosis; (iii) BEKINDA((TM))(RHB-102) - a once-
daily oral pill formulation of ondansetron with an ongoing Phase III study in
the U.S. for acute gastroenteritis and gastritis and an ongoing Phase II study
for IBS-D; (iv) RHB-106 - an encapsulated bowel preparation licensed to Salix
Pharmaceuticals, Ltd.; (v) YELIVA((TM)) (ABC294640) - a Phase II-stage, orally-
administered, first-in-class SK2 selective inhibitor targeting multiple
oncology, inflammatory and gastrointestinal indications; (vi) MESUPRON(®) - a
Phase II-stage first-in-class uPA inhibitor, administered by oral capsule,
targeting gastrointestinal and other solid tumors; (vii) RP101 -currently
subject to an option-to-acquire by RedHill, RP101 is a Phase II-stage first-in-
class Hsp27 inhibitor, administered by oral tablet, targeting pancreatic and
other gastrointestinal cancers; (viii)RIZAPORT((TM)) (RHB-103) - an oral thin
film formulation of rizatriptan for acute migraines, with a U.S. NDA currently
under discussion with the FDA and marketing authorization received in Germany in
October 2015; and (ix) RHB-101 - a once-daily oral pill formulation of the
cardio drug carvedilol.
This press release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Such statements may be
preceded by the words "intends," "may," "will," "plans," "expects,"
"anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes,"
"potential" or similar words. Forward-looking statements are based on certain
assumptions and are subject to various known and unknown risks and
uncertainties, many of which are beyond the Company's control, and cannot be
predicted or quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements. Such risks
and uncertainties include, without limitation, risks and uncertainties
associated with (i) the initiation, timing, progress and results of the
Company's research, manufacturing, preclinical studies, clinical trials, and
other therapeutic candidate development efforts; (ii) the Company's ability to
advance its therapeutic candidates into clinical trials or to successfully
complete its preclinical studies or clinical trials; (iii) the extent and number
of additional studies that the Company may be required to conduct and the
Company's receipt of regulatory approvals for its therapeutic candidates, and
the timing of other regulatory filings, approvals and feedback; (iv) the
manufacturing, clinical development, commercialization, and market acceptance of
the Company's therapeutic candidates; (v) the Company's ability to establish and
maintain corporate collaborations; (vi) the Company's ability to acquire
products approved for marketing in the U.S. that achieve commercial success and
build its own marketing and commercialization capabilities; (vii) the
interpretation of the properties and characteristics of the Company's
therapeutic candidates and of the results obtained with its therapeutic
candidates in research, preclinical studies or clinical trials; (viii) the
implementation of the Company's business model, strategic plans for its business
and therapeutic candidates; (ix) the scope of protection the Company is able to
establish and maintain for intellectual property rights covering its therapeutic
candidates and its ability to operate its business without infringing the
intellectual property rights of others; (x) parties from whom the Company
licenses its intellectual property defaulting in their obligations to the
Company; (xi) estimates of the Company's expenses, future revenues capital
requirements and the Company's needs for additional financing; (xii) competitive
companies and technologies within the Company's industry; and (xiii) the impact
of the political and security situation in Israel on the Company's business.
More detailed information about the Company and the risk factors that may affect
the realization of forward-looking statements is set forth in the Company's
filings with the Securities and Exchange Commission (SEC), including the
Company's Annual Report on Form 20-F filed with the SEC on February 25, 2016.
All forward-looking statements included in this Press Release are made only as
of the date of this Press Release. We assume no obligation to update any written
or oral forward-looking statement unless required by law.
(1) All financial highlights are approximate and are rounded to the nearest
hundreds of thousands.
(2) Including cash, bank deposits and short-term investments.
(3) Gomma AI et al., Hepatocellular carcinoma: epidemiology, risk factors and
pathogenesis, World J Gastroenterol, 2008 Jul 21; 14(27): 4300-8.
(4) Alcedo KP, Thanigachalam S, Naser SA. RHB-104 triple antibiotics combination
in culture is bactericidal and should be effective for treatment of Crohn's
disease associated with Mycobacterium paratuberculosis, Gut Pathogens,
2016, 8:32.
(5) World Health Organization (WHO), Fact sheet No° 103, January 2016.
REDHILL BIOPHARMA LTD.
CONDENSED INTERIM STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited)
Three months ended Six months ended
June 30, June 30,
--------------------- -----------------------
2016 2015 2016 2015
--------------------- -----------------------
U.S. dollars in thousands
---------------------------------------------
REVENUES 1 1 1 2
RESEARCH AND DEVELOPMENT
EXPENSES, net 6,031 5,090 10,707 8,919
GENERAL, ADMINISTRATIVE AND
BUSINESS DEVELOPMENT EXPENSES 1,164 801 2,391 1,728
------------ -------- ------------- ---------
OPERATING LOSS 7,194 5,890 13,097 10,645
------------ -------- ------------- ---------
FINANCIAL INCOME 666 167 1,025 91
FINANCIAL EXPENSES 24 873 4 684
------------ -------- ------------- ---------
FINANCIAL EXPENSES
(INCOME), net (642 ) 706 (1,021 ) 593
------------ -------- ------------- ---------
LOSS AND COMPREHENSIVE LOSS 6,552 6,596 12,076 11,238
------------ -------- ------------- ---------
LOSS PER ORDINARY SHARE (U.S.
dollars):
Basic 0.05 0.07 0.09 0.12
------------ -------- ------------- ---------
Diluted 0.06 0.07 0.10 0.12
------------ -------- ------------- ---------
REDHILL BIOPHARMA LTD.
CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION
(Unaudited)
June 30, December 31,
2016 2015
------------------------------
U.S. dollars in thousands
------------------------------
CURRENT ASSETS:
Cash and cash equivalents 3,424 21,516
Bank deposits 36,766 36,622
Financial assets at fair value through profit
or loss 7,542 -
Prepaid expenses and receivables 2,180 2,372
-------------- ---------------
49,912 60,510
-------------- ---------------
NON-CURRENT ASSETS:
Bank deposits 137 134
Fixed assets 148 124
Intangible assets 6,060 6,060
-------------- ---------------
6,345 6,318
-------------- ---------------
TOTAL ASSETS 56,257 66,828
-------------- ---------------
CURRENT LIABILITIES:
Accounts payable and accrued expenses 4,755 3,514
Payable in respect of intangible asset
purchase 2,000 2,000
-------------- ---------------
6,755 5,514
-------------- ---------------
NON-CURRENT LIABILITIES -
Derivative financial instruments 522 1,237
-------------- ---------------
TOTAL LIABILITIES 7,277 6,751
-------------- ---------------
EQUITY:
Ordinary shares 344 343
Additional paid-in capital 120,730 120,621
Warrants 1,057 1,057
Accumulated deficit (73,151 ) (61,944 )
-------------- ---------------
TOTAL EQUITY 48,980 60,077
-------------- ---------------
TOTAL LIABILITIES AND EQUITY 56,257 66,828
-------------- ---------------
REDHILL BIOPHARMA LTD.
CONDENSED INTERIM STATEMENTS OF CASH FLOWS
(Unaudited)
Three months ended Six months ended
June 30, June 30,
--------------------------- -----------------------------
2016 2015 2016 2015
---------------------------------------------------------
U.S. dollars in thousands
---------------------------------------------------------
OPERATING
ACTIVITIES:
Comprehensive loss (6,552 ) (6,596 ) (12,076 ) (11,238 )
------------- ------------- -------------- --------------
Adjustments in
respect of income
and expenses not
involving cash
flow:
Share-based
compensation to
employees and
service providers 495 294 869 616
Depreciation 11 8 21 17
Unrealized losses
(gains) on
derivative
financial
instruments (514 ) 869 (715 ) 621
Fair value gains
on financial
assets at fair
value through
profit or loss (54 ) - (62 ) -
Revaluation of
bank deposits (89 ) 14 (147 ) 10
Exchange
differences in
respect of cash
and cash
equivalents 41 (114 ) (41 ) 53
------------- ------------- -------------- --------------
(110 ) 1,071 (75 ) 1,317
------------- ------------- -------------- --------------
Changes in assets
and liability
items:
Decrease
(increase) in
prepaid expenses
and receivables (248 ) 796 192 1,502
Increase in
accounts payable
and accrued
expenses 1,173 49 1,241 367
------------- ------------- -------------- --------------
925 845 1,433 1,869
------------- ------------- -------------- --------------
Net cash used in
operating
activities (5,737 ) (4,680 ) (10,718 ) (8,052 )
------------- ------------- -------------- --------------
INVESTING
ACTIVITIES:
Purchase of fixed
assets (16 ) (5 ) (45 ) (7 )
Purchase of
intangible assets - (1,500 ) - (1,575 )
Change in
investment in
current bank
deposits (2,000 ) 5,000 - (2,000 )
Purchase of
financial assets
at fair value
through profit or
loss (908 ) - (7,480 ) -
------------- ------------- -------------- --------------
Net cash provided
by (used in)
investing
activities (2,924 ) 3,495 (7,525 ) (3,582 )
------------- ------------- -------------- --------------
FINANCING
ACTIVITIES:
Proceeds from
issuance of
ordinary shares,
net of expenses - - - 13,198
Exercise of
options into
ordinary shares,
net 100 36 110 36
------------- ------------- -------------- --------------
Net cash provided
by financing
activities 100 36 110 13,234
------------- ------------- -------------- --------------
INCREASE
(DECREASE) IN CASH
AND CASH
EQUIVALENTS (8,561 ) (1,149 ) (18,133 ) 1,600
EXCHANGE
DIFFERENCES ON
CASH AND CASH
EQUIVALENTS (41 ) 114 41 (53 )
BALANCE OF CASH
AND CASH
EQUIVALENTS AT
BEGINNING OF
PERIOD 12,026 8,474 21,516 5,892
------------- ------------- -------------- --------------
BALANCE OF CASH
AND CASH
EQUIVALENTS AT END
OF PERIOD 3,424 7,439 3,424 7,439
------------- ------------- -------------- --------------
Supplementary
information on
interest received
in cash 4 54 15 80
------------- ------------- -------------- --------------
Supplementary
information on
investing
activities not
involving
cashflows -
Purchase of
intangible assets - - - 2,000
------------- ------------- -------------- --------------
Company contact:
Adi Frish
Senior VP Business Development & Licensing
RedHill Biopharma
+972-54-6543-112
adi(at)redhillbio.com
IR contact (U.S.):
Marcy Nanus
Senior Vice President
The Trout Group
+1-646-378-2927
Mnanus(at)troutgroup.com
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: RedHill Biopharma Ltd. via GlobeNewswire
[HUG#2030678]
Datum: 26.07.2016 - 13:00 Uhr
Sprache: Deutsch
News-ID 485409
Anzahl Zeichen: 37384
contact information:
Town:
Tel-Aviv
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 209 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"RedHill Biopharma Reports 2016 Second Quarter Financial Results"
steht unter der journalistisch-redaktionellen Verantwortung von
RedHill Biopharma Ltd. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
